Opinion: To make advanced therapies, we need to industrialize personalization
What’s the best way to measure the real rate of progress in personalized cell therapies, gene therapies, and other advanced therapies?
I’ve been tracking the ever-growing flow of reports about these therapies in scientific journals and press releases for 15 years, ever since I co-led the passage of California’s $3 billion Stem Cell Research and Cures Act in 2004.
